Evaluation of in vivo hypoglycemic potential of 4-ethyloxychalcone in alloxan-induced diabetic rats

Evaluation of in vivo hypoglycemic potential of 4-ethyloxychalcone in alloxan-induced diabetic rats The presently available therapies for type 2 diabetes have not been able to achieve normoglycemic status in a majority of the patients which may be either due to the limitations of the drug itself or its side effects. In an effort to develop potent and safe oral antidiabetic agents, 4-ethyloxychalcone, which was found to be the most potent antiglycating agent in our previous study, has been evaluated for its in vivo hypoglycemic activity using an alloxanized diabetic rat model. The diabetes was induced in rats by injection of intraperitoneal alloxan. However, the oral route was used for the administration of 4-ethyloxychalcone. A significant glucose-lowering effect (P < 0.05) comparable with the standard glibenclamide has been observed for 4-ethyloxychalcone in an oral glucose tolerance test. 4-Ethyloxychalcone also produced a significant decrease (P < 0.05) in fasting blood glucose levels during the 42 days of treatment. Furthermore, a significant lowering (P < 0.05) of glycated hemoglobin (HbA1C ) level was also shown by 4-ethyloxychalcone after 42 days of treatment. Thus, 4-ethyloxychalcone might be regarded as a potential hypoglycemic agent that can act as a platform for the development of future antidiabetic drugs. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Research on Chemical Intermediates Springer Journals

Evaluation of in vivo hypoglycemic potential of 4-ethyloxychalcone in alloxan-induced diabetic rats

Loading next page...
 
/lp/springer_journal/evaluation-of-in-vivo-hypoglycemic-potential-of-4-ethyloxychalcone-in-wg8CVGdFwQ
Publisher
Springer Netherlands
Copyright
Copyright © 2015 by Springer Science+Business Media Dordrecht
Subject
Chemistry; Catalysis; Physical Chemistry; Inorganic Chemistry
ISSN
0922-6168
eISSN
1568-5675
D.O.I.
10.1007/s11164-015-2266-0
Publisher site
See Article on Publisher Site

Abstract

The presently available therapies for type 2 diabetes have not been able to achieve normoglycemic status in a majority of the patients which may be either due to the limitations of the drug itself or its side effects. In an effort to develop potent and safe oral antidiabetic agents, 4-ethyloxychalcone, which was found to be the most potent antiglycating agent in our previous study, has been evaluated for its in vivo hypoglycemic activity using an alloxanized diabetic rat model. The diabetes was induced in rats by injection of intraperitoneal alloxan. However, the oral route was used for the administration of 4-ethyloxychalcone. A significant glucose-lowering effect (P < 0.05) comparable with the standard glibenclamide has been observed for 4-ethyloxychalcone in an oral glucose tolerance test. 4-Ethyloxychalcone also produced a significant decrease (P < 0.05) in fasting blood glucose levels during the 42 days of treatment. Furthermore, a significant lowering (P < 0.05) of glycated hemoglobin (HbA1C ) level was also shown by 4-ethyloxychalcone after 42 days of treatment. Thus, 4-ethyloxychalcone might be regarded as a potential hypoglycemic agent that can act as a platform for the development of future antidiabetic drugs.

Journal

Research on Chemical IntermediatesSpringer Journals

Published: Sep 21, 2015

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve Freelancer

DeepDyve Pro

Price
FREE
$49/month

$360/year
Save searches from Google Scholar, PubMed
Create lists to organize your research
Export lists, citations
Read DeepDyve articles
Abstract access only
Unlimited access to over
18 million full-text articles
Print
20 pages/month
PDF Discount
20% off